The state recognized the nonprofit organization for honoring its history and ongoing contributions to the community and the ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Summit Therapeutics Inc (SMMT) stock saw a decline, ending the day at $24.56 which represents a decrease of $-1.66 or -6.33% from the prior close of $26.22. The stock opened at $26.17 and touched a ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

Citi analyst Yigal Nochomovitz maintained a Buy rating on Applied Therapeutics (APLT – Research Report) yesterday and set a price target ...

Why the Gut Microbiome is Critical to Children’s Health: Harnessing Microbiome Science to End Malnutrition” is a seminal ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape ...

The FDA issued draft guidance on oncology clinical trials, taking the first steps toward formalizing a position that it's ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...